LRCX — Lam Research Balance Sheet
0.000.00%
- $317.78bn
- $314.07bn
- $23.23bn
Annual balance sheet for Lam Research, fiscal year end - June 28th, USD millions except per share, conversion factor applied.
2022 June 26th | 2023 June 25th | 2024 June 30th | 2025 June 29th | 2026 June 28th | |
|---|---|---|---|---|---|
| Period Length: | 52 W | 52 W | 53 W | 52 W | 52 W |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 3,658 | 5,375 | 5,848 | 6,391 | 5,579 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 4,314 | 2,823 | 2,519 | 3,378 | 5,340 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 12,285 | 13,228 | 12,883 | 14,517 | 15,611 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1,874 | 2,099 | 2,463 | 2,716 | 3,354 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 17,196 | 18,782 | 18,745 | 21,345 | 23,530 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4,565 | 4,185 | 4,338 | 6,568 | 5,937 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 10,917 | 10,571 | 10,205 | 11,484 | 11,059 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 6,278 | 8,210 | 8,539 | 9,862 | 12,471 |
| Total Liabilities & Shareholders' Equity | 17,196 | 18,782 | 18,745 | 21,345 | 23,530 |
| Total Common Shares Outstanding |